FB102 Hits Primary Endpoint in Phase 1b Vitiligo Trial, Setting Stage for Forte Surge

summarizeSummary

FB102 demonstrated statistically significant and clinically meaningful improvement in vitiligo during a placebo-controlled Phase 1b trial, backed by a strong safety profile. The results validate the drug's potential across multiple autoimmune indications and mark a pivotal moment for Forte.

check_boxKey Events · Product Development and Regulatory · FBRX

• FB102 Phase 1b Vitiligo Trial Meets Primary Endpoint

  FB102 achieved a 29.6% mean FVASI improvement from baseline at week 24 compared to 7.9% for placebo (p=0.020), with statistically significant separation by day 64 (p=0.023).

• Greater Efficacy in Severe Disease Subgroup

  In subjects with baseline FVASI ≥0.75, FB102 showed a 43.2% mean improvement (p=0.006), with 58.8% achieving FVASI50 and 23.5% achieving FVASI75.

• Clean Safety Profile

  FB102 was well-tolerated with only mild to moderate adverse events, comparing favorably to placebo and avoiding the severe safety concerns associated with JAK inhibitors.

• Durable and Progressive Improvement

  84% of FB102-treated subjects improved from baseline, with continued improvement through week 24 after the 12-week treatment period ended, suggesting a durable treatment effect.

auto_awesomeAnalysis · FBRX · Life Sciences

Forte Biosciences announced that its lead drug candidate, FB102, achieved statistically significant improvement in vitiligo during a Phase 1b study. The drug delivered a 29.6% mean FVASI improvement at week 24 versus placebo (p=0.020), with separation evident as early as day 64. Among patients with more severe disease, the improvement reached 43.2% (p=0.006). The safety profile was clean, marked by only mild to moderate side effects. These results validate FB102's mechanism and de-risk the broader autoimmune pipeline, including the ongoing Phase 2 celiac disease trial. The data position FB102 competitively against oral JAK inhibitors, which carry black box warnings, and open a large market opportunity in vitiligo affecting ~2 million Americans. This is a major inflection point for the company, potentially transforming its valuation and partnership prospects.